Is Synacor, Inc. (NASDAQ:SYNC) Overpaying Its CEO?

The field of medicine has greatly benefited from technology. Technology has opened new doorways for the pharmaceutical industry and has enabled it to formulate medicines and create therapies that are targeted to a specific problem and treat its root cause. This has enhanced the quality of human life and increased life expectancy. Diseases that were once thought to be deadly are now curable, thanks to the integration of technology and medicine. A stream of the pharma industry is bio pharmacy. Biopharmaceuticals, also known as biological medical products, is a pharmaceutical drug derived from biological sources. It is the application of living organisms or extractions, by-products, components of living organisms to treat, prevent, or relieve diseases.


Investing in biopharma companies can be a tricky business. The success of these companies is dependent on successful trials of their products. If the product is successful in clinical trials, the company can expect good profits and the investors can benefit from it. But if the product fails in the trial stage, then the company might have to wait longer for profits. Hence, such investments are promising if invested in for the long term. Picking companies that are researching high demand areas like cancer or diabetes may give you good returns, as its success can generate great returns.


Syros Pharmaceuticals is a biopharmaceutical company that is engaged in the development of a treatment for cancer and monogenic diseases. The company is also focusing on building a product pipeline of gene control medicines. Its lead product candidates include SY-1425 (selective retinoid acid receptor alpha agonist) for patients with genomically defined subsets of acute myeloid leukemia and myelodysplastic syndrome; SY-1365 (selective cyclin-dependent kinase 7 inhibitors) for treating patients with solid tumors, ovarian, breast and blood cancers. The company has a target discovery and research collaboration with Incyte to identify therapeutic targets, and a license agreement with TMRC Co. Ltd. for the development and commercialization of SY-1425. The company was formerly known as LS22 but changed to its current name in 2012. Syros Pharmaceuticals was founded in 2011 and is headquartered in Cambridge, Massachusetts.


Stocks of Syros Pharmaceuticals are listed on the Nasdaq exchange under the ticker ‘SYRS’. The NASDAQ: SYRS stock at is currently traded for $11.91. Analysts have arrived at a ‘buy’ consensus rating for the stock. NASDAQ: SYRS has a potential upside of 21.7% with a price target of $14.50, according to analysts. The company has a market cap of $545.03 million. Before the pandemic, the stock traded for $5.15 and has increased to its current price by 131.3% since then. The company has reported EPS of -$0.38 in the first quarter of 2020.You can check the latest price at apps stock.


Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.